ARTHEx Biotech Upsizes Series B Financing Round to $87 millones

by ARTHEx Biotech

Proceeds to support further clinical development of lead program ATX-01 in Myotonic Dystrophy Type1, a unique therapy currently in Phase I-IIa, targeting miR23b

Read more

ARTHEx Biotech, backed by Columbus Venture Partners, receives IND Clearance from FDA to Initiate the Phase I-IIa ArthemiR™ Trial of ATX-01 for Myotonic Dystrophy Type 1 (DM1)

by ARTHEx Biotech

ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs backed by Columbus Venture Partners, has announced that the ...

Read more
Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

New breakthrough in developing more pers...

by Universitat de Barcelona

The results show that adenocarcinoma exhibits much more active and fun...

Photos Stream